Sanofi (NASDAQ:SNY) ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ET
Company Participants
Thomas Kudsk – IR
Jiwon Oh – MD, PhD, St. Michael’s Hospital, University of Toronto, Toronto, Canada
Robert Fox – MD, Mellen Center for MS, Cleveland Clinic, Cleveland, USA
Houman Ashrafian – EVP, Head of Research and Development
Erik Wallstroem – Global Senior VP, Head, Neurology Development
Conference Call Participants
Peter Verdult – Citi
Colin Wyatt – Jefferies
Luisa Hector – Berenberg
Emily Field – Barclays
Simon Baker – Atlantic Redburn
Richard Vosser – JPMorgan
Emmanuel Papadakis – Deutsche Bank
Graham Parry – Bank of America
Seamus Fernandez – Guggenheim
Peter Verdult – Jefferies
Eric Berrigaud – Stifel Nicolaus
Thomas Kudsk
Good afternoon from Copenhagen, and welcome to the Sanofi Investor Science Call from the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis or ECTRIMS 2024. I’m Thomas Kudsk from the Investor Relations team at Sanofi and we are here today for an update on Tolebrutinib, Sanofi’s new medicine, intending to benefit patients with certain forms of multiple sclerosis.
Tolebrutinib recently had three Phase 3 readouts and we are pleased already being able to present this data today. This event has a presentation which is available for download at sanofi.com. We plan to spend about 20 to 25 minutes on the presentation and then we got the same time available for Q&A. It is Friday afternoon so we plan to end the bid before 05:00 p.m. local time.
Before we get started, I would like to thank Elise, Marie and Caroline from the IR team for organizing the call. I’ll also remind everyone that questions can be asked via Zoom using the raise hand function on your phone. There are instructions on the second last slide. Alternatively, please drop an email to thomas.larsen@sanofi.com. We’ll make sure to
Read the full article here